Cytosorbents Corp Files 8-K on Operations and Financials

TL;DR

CYTOSORBENTS CORP FILED AN 8-K ON OCT 1ST DETAILING OPERATIONS AND FINANCIALS.

AI Summary

Cytosorbents Corporation filed an 8-K on October 1, 2024, reporting on its results of operations and financial condition, as well as other events. The filing also includes financial statements and exhibits. The company was formerly known as MedaSorb Technologies CORP and GILDER ENTERPRISES INC.

Why It Matters

This 8-K filing provides investors with crucial updates on Cytosorbents Corporation's operational and financial status, including any significant events that occurred.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate material adverse events.

Key Players & Entities

• Cytosorbents Corporation (company) — Registrant
• October 1, 2024 (date) — Date of Earliest Event Reported
• MedaSorb Technologies CORP (company) — Former Company Name
• GILDER ENTERPRISES INC (company) — Former Company Name
• 305 College Road East (address) — Principal Executive Offices
• Princeton, New Jersey (location) — Principal Executive Offices Location

FAQ

Key Financial Figures

• $0.001 — e on which registered Common Stock, $0.001 par value CTSO The Nasdaq Stock Marke

Filing Documents

• tm2425307d1_8k.htm (8-K) — 27KB
• tm2425307d1_ex99-1.htm (EX-99.1) — 21KB
• tm2425307d1_ex99-1img001.jpg (GRAPHIC) — 53KB
• 0001104659-24-104669.txt ( ) — 296KB
• ctso-20241001.xsd (EX-101.SCH) — 3KB
• ctso-20241001_lab.xml (EX-101.LAB) — 33KB
• ctso-20241001_pre.xml (EX-101.PRE) — 22KB
• tm2425307d1_8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operation and Financial Condition On October 1, 2024, CytoSorbents Corporation (the "Company") issued a press release announcing certain preliminary financial results for the quarter ended September 30, 2024, including estimated ranges for quarterly product sales and product gross margins. A copy of the press release is furnished herewith as Exhibit 99.1.*

01

Item 8.01 Other Events The Company has submitted its DrugSorb-ATR medical device De Novo marketing application to the U.S. Food and Drug Administration (the "FDA") to reduce the severity of perioperative bleeding in patients on ticagrelor undergoing coronary artery bypass graft surgery. The FDA has previously granted Breakthrough Device Designation to DrugSorb-ATR to address this major unmet medical need, making it eligible for priority review. The Company has also completed its DrugSorb-ATR Health Canada Medical Device License application, which will be submitted with the expected near-term receipt of Medical Device Single Audit Program certification.

01

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated October 1, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 1, 2024 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR